NCT02391480 - A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

April 14, 2015

Primary Completion Date

July 5, 2019

Study Completion Date

July 5, 2019

Conditions

CancerBreast CancerNon-Small Cell Lung CancerAcute Myeloid Leukemia (AML)Multiple MyelomaProstate CancerSmall Cell Lung CancerNon-Hodgkins Lymphoma

Interventions

DRUG

ABBV-075

ABBV-075 Oral tablets

DRUG

Venetoclax

Venetoclax tablets, film-coated

Trial Locations (10)

Duke Univ Med Ctr /ID# 154647, Durham

Indiana Univ School Medicine /ID# 132946, Indianapolis

Mary Crowley Cancer Research /ID# 154059, Dallas

Univ TX, MD Anderson /ID# 132276, Houston

UT MD Anderson Cancer Center /ID# 164122, Houston

City of Hope /ID# 154053, Duarte

UC Davis Comp Cancer Ctr /ID# 154644, Sacramento

Scottsdale Healthcare /ID# 132963, Scottsdale

Yale University /ID# 136982, New Haven

University of Chicago /ID# 155453, Chicago